CJC-1295 research: what the studies measured

What Is a GHRH Analog?

A GHRH analog is a synthetic molecule that mimics growth-hormone-releasing hormone, the hypothalamic peptide that stimulates the pituitary to make and release growth hormone. CJC-1295 research begins here: the molecule is a tetrasubstituted version of hGRF(1-29), the active 1-29 fragment of human GHRH. Native GHRH is destroyed within minutes by the enzyme dipeptidylpeptidase-IV (DPP-IV); the D-Ala substitution at position 2 blocks that cleavage, and three further substitutions stabilize the molecule against deamidation and oxidation ^[2].

The analog binds the GHRH receptor — a class-B G-protein-coupled receptor on pituitary somatotrophs — and activates the Gs/cAMP/PKA cascade that drives growth-hormone gene transcription and release ^[2]. Because it acts upstream, on the body's own GH machinery, it raises growth hormone while preserving the pituitary's natural pulse pattern, which a flat infusion of hormone would not.

The albumin-conjugate data that defined the molecule

CJC-1295 was the lead compound from a screen of hGRF(1-29) analogs carrying a maleimidopropionyl-lysine handle designed to bond covalently to circulating serum albumin. In Sprague-Dawley rats, the albumin-conjugated analog produced a 4-fold increase in growth-hormone area-under-the-curve over two hours compared with unconjugated hGRF(1-29), remained detectable in plasma beyond 72 hours, and resisted DPP-IV cleavage in a cell-free assay ^[2].

That result is the engineering proof: covalent albumin binding converts a peptide that normally clears in minutes into one that circulates for days. Everything distinctive about the DAC form — the multi-day half-life, the once-daily-or-less dosing in later studies — traces back to this conjugation chemistry.

What does the published human research on CJC-1295 actually show?

The published human record is limited but consistent. In healthy adults, single subcutaneous doses of 30 or 60 µg/kg produced dose-dependent 2- to 10-fold increases in mean growth hormone for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days; after multiple doses IGF-1 stayed above baseline up to 28 days, and the estimated CJC-1295 half-life was 5.8–8.1 days ^[1]. A second study in healthy young men showed a single 60 or 90 µg/kg dose raised basal growth hormone ~7.5-fold and mean GH ~46% and IGF-1 ~45% one week later, with pulsatile secretion unchanged ^[3]. A proteomic study in 11 healthy men found reproducible serum-protein shifts that tracked linearly with IGF-1, identifying candidate biomarkers of axis activation ^[5].

That is essentially the human evidence base: early-phase pharmacokinetic and biomarker work. A ConjuChem Phase 2 program in HIV-associated visceral obesity was discontinued, and no large efficacy or long-term safety trial exists ^[1]. For the full kinetics, see what the human research shows carried forward on the GH / IGF-1 axis research page.

The once-daily mouse-growth experiment

One preclinical study makes the long-acting design vivid. In GHRH-knockout mice — animals that cannot grow normally because they lack the hormone — 2 µg of CJC-1295 given once every 24 hours fully normalized body weight and length, while dosing every 48 or 72 hours was progressively less effective; treatment also raised pituitary GH mRNA ^[4].

The takeaway is mechanistic, not a dosing instruction: a single daily dose of the long-acting analog was sufficient to restore GH-axis-dependent growth in an animal that otherwise could not grow. It is the clearest demonstration that sustained GHRH-receptor stimulation, delivered infrequently, can drive the downstream axis.

CJC-1295 and Ipamorelin: The Two-Receptor Rationale

The CJC-1295 and ipamorelin pairing is common in research discussion for one reason: the two act on different receptors. CJC-1295 is a GHRH analog (GHRH receptor); ipamorelin is a growth-hormone-releasing peptide that works through the ghrelin/GHS receptor. Because the pathways are distinct, co-administration of a GHRH analog with a GHRP produces growth-hormone release greater than the sum of either agent alone ^[10].

That supra-additive acute response — not any controlled long-term outcome trial — is the entire published basis for the combination. There is no controlled human study of the specific CJC-1295-plus-ipamorelin pairing for body composition or aging, so the "stack" rests on receptor logic and the acute GH synergy, nothing more. The deeper treatment lives on the GH / IGF-1 axis research page.

CJC-1295 Among GHRH Analogs (Sermorelin, Tesamorelin)

Comparing CJC-1295 vs sermorelin and tesamorelin clarifies where it sits. Sermorelin is essentially GHRH(1-29) itself — short-acting, historically used in diagnostic and pediatric GH-deficiency settings. Tesamorelin is a stabilized GHRH analog that is FDA-approved for HIV-associated lipodystrophy; in a randomized trial, tesamorelin 2 mg subcutaneously daily reduced visceral adipose tissue and liver fat versus placebo ^[6]. That trial is the closest approved-drug benchmark for what GHRH-axis stimulation can achieve clinically.

CJC-1295 differs in two ways: the DAC variant's albumin conjugation gives it a far longer half-life than sermorelin or tesamorelin, and — critically — it is not approved anywhere, with only short early-phase human data behind it. A 2024/2025 Nature Reviews Endocrinology review synthesizes the pharmacology of the whole GHRH-analog class, including CJC-1295, sermorelin and tesamorelin ^[11].

What the broader analog class has shown

Some of the most interesting GHRH-analog findings come from the class rather than from CJC-1295 itself, and they map the directions researchers are watching. Agonistic GHRH analogs promoted wound healing in experimental models ^[14], and a GHRH-expression plasmid improved osteoporosis and skin-damage endpoints in aged mice ^[15] — tissue-level effects that motivate interest in the somatopause, the age-related decline in GH/IGF-1 activity. On metabolism, growth hormone and GH-secretagogue effects on nitrogen balance and urea kinetics have been characterized, sketching the substrate-metabolism profile of axis stimulation ^[13].

A point worth keeping straight: these are studies of the GHRH-analog class and of GH/IGF-1 stimulation in general, not controlled trials of CJC-1295 in healthy adults. They explain why the molecule is studied; they do not stand in for the human efficacy and safety data that CJC-1295 simply does not have.

Pulsatility, infusion, and why timing matters

One older finding makes the CJC-1295 pulsatility result more striking. Episodic GHRH administration was shown to be more effective than continuous infusion at driving growth-hormone pulses in humans ^[10] — the pituitary responds to a pulsed signal better than to a flat one. That is the backdrop against which the Ionescu and Frohman observation lands: under sustained stimulation by the long-acting analog, the frequency and magnitude of pulsatile GH secretion were unaltered ^[3].

In other words, the albumin-anchored analog raises the baseline without flattening the body's own rhythm — the pituitary keeps firing in pulses. Whether that pharmacological nicety translates into any clinical advantage is untested, but it is the mechanistic detail that distinguishes a long-acting GHRH analog from a simple continuous hormone infusion.

On the anti-doping record

CJC-1295 also appears in the analytical-chemistry literature. It was structurally identified by high-resolution LC-MS/MS as the active ingredient in an unknown "GHRH" pharmaceutical preparation seized in an anti-doping context ^[8] — a reminder that the compound circulates in gray-market products and that detection assays for it are well established. CJC-1295 is prohibited at all times in sport under Section S2 of the WADA Prohibited List, and is banned by bodies including the NCAA. For an athlete, that status is not a footnote; it is the headline.